{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:49:08Z","timestamp":1784630948462,"version":"3.55.0"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0104160","type":"journal-article","created":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T23:04:59Z","timestamp":1406934299000},"page":"e104160","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":57,"title":["Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment"],"prefix":"10.1371","volume":"9","author":[{"given":"Jiamei","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"key":"ref1","first-page":"CD006654","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","volume":"17","author":"K Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","article-title":"Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies","volume":"21","author":"A Zuddas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.brainres.2008.03.023","article-title":"Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments","volume":"1211","author":"DT Balu","year":"2008","journal-title":"Brain Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.npp.1300089","article-title":"Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients","volume":"28","author":"JR Bustillo","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"J Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"ref6","first-page":"CD008120","article-title":"Second-generation antipsychotics for anxiety disorders","volume":"12","author":"AM Depping","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study","volume":"111","author":"JK Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"CU Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0269881110368872","article-title":"Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics","volume":"25","author":"O Osuntokun","year":"2011","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"R Perez-Iglesias","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk","volume":"119","author":"S Stahl","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ecl.2013.05.006","article-title":"Effects of antipsychotic medications on appetite, weight, and insulin resistance","volume":"42","author":"C Deng","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"CU Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.mp.4001009","article-title":"Significant dissociation of brain and plasma kinetics with antipsychotics","volume":"7","author":"J Tauscher","year":"2002","journal-title":"Mol Psychiatry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"HY Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design","volume":"127","author":"R Coccurello","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H<sub>1<\/sub> and H<sub>3<\/sub> receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain","volume":"34","author":"C Deng","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H<sub>1<\/sub>-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"WK Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"A Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2011.09.003","article-title":"Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels","volume":"22","author":"K Weston-Green","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pbb.2011.07.019","article-title":"Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations","volume":"100","author":"G Remington","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","article-title":"Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia","volume":"6","author":"DH Kim","year":"2009","journal-title":"Neurotherapeutics"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"M He","year":"2013","journal-title":"CNS Drugs"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"Antipsychotic drug-induced weight gain mediated by histamine H<sub>1<\/sub> receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"SF Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"D Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-011-2211-x","article-title":"Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication","volume":"216","author":"J Vehof","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FBP.0b013e3282f62c66","article-title":"Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat","volume":"19","author":"N Davoodi","year":"2008","journal-title":"Behav Pharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H<sub>1<\/sub> receptor expression","volume":"33","author":"M Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10571-011-9663-8","article-title":"A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats","volume":"31","author":"E Sejima","year":"2011","journal-title":"Cell Mol Neurobiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145713000862","article-title":"Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects","volume":"17","author":"S Skrede","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.psyneuen.2014.01.018","article-title":"Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats","volume":"42","author":"M He","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpsychires.2012.01.010","article-title":"Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain","volume":"46","author":"RP Souza","year":"2012","journal-title":"J Psychiatr Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"J Fern\u00f8","year":"2011","journal-title":"PLoS ONE"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e33548","DOI":"10.1371\/journal.pone.0033548","article-title":"Alterations to Melanocortinergic GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine","volume":"7","author":"K Weston-Green","year":"2012","journal-title":"PLoS ONE"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1017\/S1461145713001697","article-title":"Hypothalamic ghrelin signalling mediates olanzapine induced hyperphagia and weight gain in female rats","volume":"17","author":"Q Zhang","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/j.1749-6632.2010.05905.x","article-title":"Three years with adult human brown adipose tissue","volume":"1212","author":"J Nedergaard","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.numecd.2006.07.009","article-title":"The role of brown adipose tissue in human obesity","volume":"16","author":"S Cinti","year":"2006","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pnpbp.2014.02.003","article-title":"Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats","volume":"51","author":"Q Zhang","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"A Stefanidis","year":"2008","journal-title":"Obesity"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e93310","DOI":"10.1371\/journal.pone.0093310","article-title":"Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats","volume":"9","author":"Y Hu","year":"2014","journal-title":"PLoS ONE"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2006.04.002","article-title":"Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation","volume":"3","author":"M Uldry","year":"2006","journal-title":"Cell Metab"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3858\/emm.2012.44.9.062","article-title":"Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics","volume":"44","author":"JE Oh","year":"2012","journal-title":"Exp Mol Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuroscience.2012.04.068","article-title":"Loss of histaminergic modulation of thermoregulation and energy homeostasis in obese mice","volume":"217","author":"J Sethi","year":"2012","journal-title":"Neuroscience"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/oby.20605","article-title":"Evidence for the role of AMPK in regulating PGC-1 alpha expression and mitochondrial proteins in mouse epididymal adipose tissue","volume":"22","author":"Z Wan","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0269881112449396","article-title":"Reducing olanzapine-induced weight gain side-effect by betahistine: a study in the rat model","volume":"26","author":"C Deng","year":"2012","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-012-2935-2","article-title":"Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine\u2013betahistine combination","volume":"226","author":"M Poyurovsky","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-007-0731-1","article-title":"Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study","volume":"192","author":"M Poyurovsky","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/00002018-200629110-00004","article-title":"Betahistine: a retrospective synopsis of safety data","volume":"29","author":"S Jeck-Thole","year":"2006","journal-title":"Drug Saf"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.pnpbp.2007.02.009","article-title":"Olanzapine treatment decreases the density of muscarinic M<sub>2<\/sub> receptors in the dorsal vagal complex of rats","volume":"31","author":"C Deng","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2010.10.039","article-title":"Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats","volume":"217","author":"K Weston-Green","year":"2011","journal-title":"Behav Brain Res"},{"key":"ref52","unstructured":"Olds RJ, Olds JR (1979) A colour atlas of the rat : dissection guide London: Wolfe Medical."},{"key":"ref53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0002-9394(01)00976-X","article-title":"Indocyanine green staining and removal of internal limiting membrane in macular hole surgery: histology and outcome","volume":"132","author":"AKH Kwok","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/03635465000280061401","article-title":"Light Microscopic Histology of Achilles Tendon Ruptures","volume":"28","author":"N Maffulli","year":"2001","journal-title":"The American Journal of Sports Medicine"},{"key":"ref55","unstructured":"Paxinos G, Watson C (2007) The rat brain in sterotaxic coordinates: Academic Press."},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"RS Kahn","year":"2008","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"AJ Goudie","year":"2002","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajp.2012.05.005","article-title":"Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis","volume":"5","author":"N Pai","year":"2012","journal-title":"Asian J Psychiatr"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long term weight course","volume":"43","author":"S Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","article-title":"The effect of betahistine, a histamine H<sub>1<\/sub> receptor agonist\/H<sub>3<\/sub> antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"20","author":"M Poyurovsky","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"RB Zipursky","year":"2005","journal-title":"The British Journal of Psychiatry"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"The FASEB Journal"},{"key":"ref63","first-page":"24","article-title":"Effects of betahistine and of its metabolites on vestibular sensory organs","volume":"21","author":"L Botta","year":"2001","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881104042613","article-title":"Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats","volume":"18","author":"MJ Fell","year":"2004","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"GD Cooper","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/S0196-9781(02)00269-3","article-title":"Neuropeptides, food intake and body weight regulation: a hypothalamic focus","volume":"23","author":"JJG Hillebrand","year":"2002","journal-title":"Peptides"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"R1030","DOI":"10.1152\/ajpregu.00649.2010","article-title":"Immortalized Neurons for the Study of Hypothalamic Function","volume":"300","author":"PS Dalvi","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"LH Tecott","year":"1995","journal-title":"Nature"},{"key":"ref69","first-page":"225","article-title":"Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments","volume":"24","author":"C Das","year":"2012","journal-title":"Ann Clin Psychiatry"},{"key":"ref70","first-page":"4","article-title":"Preclinical pharmacology of neuroleptics: focus on new generation compounds","volume":"57","author":"E Richelson","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09540260801889179","article-title":"Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients","volume":"20","author":"C Correll","year":"2008","journal-title":"International Review of Psychiatry"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.pnpbp.2010.03.035","article-title":"Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole","volume":"34","author":"J Lian","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2337\/db10-0449","article-title":"Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance","volume":"59","author":"PJF Martins","year":"2010","journal-title":"Diabetes"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nm.2207","article-title":"Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance","volume":"16","author":"M Lopez","year":"2010","journal-title":"Nat Med"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cmet.2014.02.007","article-title":"Central Neural Regulation of Brown Adipose Tissue Thermogenesis and Energy Expenditure","volume":"19","author":"SF Morrison","year":"2014","journal-title":"Cell Metab"},{"key":"ref76","unstructured":"FDA (2005) Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. U.S. FDA Center for Drug Evaluation and Research."},{"key":"ref77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"M Aravagiri","year":"1999","journal-title":"Biopharm Drug Dispos"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0104160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T17:59:52Z","timestamp":1689443992000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0104160"}},"subtitle":[],"editor":[{"given":"Miguel","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":77,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0104160","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,1]]}}}